HomeCompareCHKEZ vs ABBV

CHKEZ vs ABBV: Dividend Comparison 2026

CHKEZ yields 3.12% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHKEZ wins by $506.11M in total portfolio value· pulled ahead in Year 3
10 years
CHKEZ
CHKEZ
● Live price
3.12%
Share price
$64.04
Annual div
$2.00
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$506.21M
Annual income
$476,880,843.59
Full CHKEZ calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CHKEZ vs ABBV

📍 CHKEZ pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHKEZABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHKEZ + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHKEZ pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHKEZ
Annual income on $10K today (after 15% tax)
$265.46/yr
After 10yr DRIP, annual income (after tax)
$405,348,717.05/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CHKEZ beats the other by $405,327,661.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHKEZ + ABBV for your $10,000?

CHKEZ: 50%ABBV: 50%
100% ABBV50/50100% CHKEZ
Portfolio after 10yr
$253.16M
Annual income
$238,452,807.67/yr
Blended yield
94.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CHKEZ
No analyst data
Altman Z
1.4
Piotroski
9/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHKEZ buys
0
ABBV buys
0
No recent congressional trades found for CHKEZ or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHKEZABBV
Forward yield3.12%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$506.21M$102.3K
Annual income after 10y$476,880,843.59$24,771.77
Total dividends collected$504.05M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CHKEZ vs ABBV ($10,000, DRIP)

YearCHKEZ PortfolioCHKEZ Income/yrABBV PortfolioABBV Income/yrGap
1$11,325$624.61$11,550$430.00$225.00ABBV
2$13,439$1,322.14$13,472$627.96$33.00ABBV
3← crossover$17,313$2,932.81$15,906$926.08+$1.4KCHKEZ
4$25,587$7,061.89$19,071$1,382.55+$6.5KCHKEZ
5$46,886$19,507.89$23,302$2,095.81+$23.6KCHKEZ
6$116,984$66,816.11$29,150$3,237.93+$87.8KCHKEZ
7$436,783$311,610.57$37,536$5,121.41+$399.2KCHKEZ
8$2,642,053$2,174,694.67$50,079$8,338.38+$2.59MCHKEZ
9$27,414,810$24,587,813.86$69,753$14,065.80+$27.35MCHKEZ
10$506,214,691$476,880,843.59$102,337$24,771.77+$506.11MCHKEZ

CHKEZ vs ABBV: Complete Analysis 2026

CHKEZStock

Chesapeake Energy Corporation engages in the acquisition, exploration, and development of properties for the production of oil, natural gas, and natural gas liquids (NGL) from underground reservoirs in the United States. The company holds interests in natural gas resource plays, including the Marcellus in Northern Appalachian Basin in Pennsylvania; Haynesville located in Northwestern Louisiana; Eagle Ford in South Texas; Brazos Valley in Southeast Texas; Powder River Basin in Wyoming; and Mid-Continent in Anadarko Basin of northwestern Oklahoma. As of December 31, 2019, it owned interests in approximately 13,500 oil and natural gas wells; and had estimated proved reserves of 1,572 one million barrels of oil equivalent. The company was founded in 1989 and is headquartered in Oklahoma City, Oklahoma.

Full CHKEZ Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CHKEZ vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHKEZ vs SCHDCHKEZ vs JEPICHKEZ vs OCHKEZ vs KOCHKEZ vs MAINCHKEZ vs JNJCHKEZ vs MRKCHKEZ vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.